Cardiovascular Systems: Liberty study shows lasting benefits from PVI
Cardiovascular Systems released one-year data from its LIBERTY 360 degrees clinical study in a late-breaking presentation at the 2017 Amputation Prevention Symposium in Chicago. The LIBERTY 360 degrees study is designed to evaluate the acute and long-term clinical and economic outcomes of peripheral vascular interventions in patients with peripheral artery disease, PAD. With over 1,200 patients enrolled at 51 sites across the United States, it is among the first PAD studies to investigate patients across the spectrum of symptomatic PAD. As an "all comers" study, LIBERTY 360 degrees 's novel trial design included any endovascular device FDA-approved for treatment of PAD. One-year study outcomes were presented at AMP by Dr. Jihad Mustapha, Director of Cardiac Research at Metro Health Hospital, University of Michigan Health, Wyoming, Michigan. Dr. Mustapha's presentation highlighted results in the most severe form of PAD, called critical limb ischemia, that spans RC 4-6 and where amputation prevention should be the primary goal in treating these patients. 12-month data* from LIBERTY 360 degrees showed 96% freedom from amputation in RC 4-5 and 81.7% in RC 6. In addition, CLI patients in the study showed notable improvements in Rutherford Classification, Wound Healing, and Quality of Life out to 12 months.